Novartis Ag (NVS) Gross Margin (2009 - 2026)
Novartis Ag (NVS) posted Gross Margin of 78.02% for Q2 2026, down 4.77% sequentially from 81.93% in Q2 2025, and down 391.0% YoY from 26.81% in Q2 2025.
Novartis Ag (NVS) Gross Margin (2009 - 2026) Analysis & Trends
Novartis Ag has reported Gross Margin for 18 years, with the latest figure at 78.02% in Q2 2026.
- Quarterly Gross Margin fell 391.0% year-over-year to 78.02% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 329.77% (up 21926.0% YoY) and the FY2025 annual result came in at 78.81%, up 151.0% from the prior year.
- Gross Margin declined to 78.02% in Q2 2026 per NVS's latest filing, from 81.93% in the prior quarter.
- Over five years, Gross Margin peaked at 13229571.98% in Q1 2022 and troughed at 0.42% in Q3 2022.
- A 5-year average of 1343035.41% and a median of 76.92% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin soared 824736558 bps in 2022, then slumped 1168636211 bps in 2023.
- Over 5 years, Gross Margin stood at 72.27% in 2022, then gained by 2 bps to 74.02% in 2023, then advanced by 4 bps to 76.92% in 2024, then climbed by 7 bps to 81.93% in 2025, then fell by 5 bps to 78.02% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 78.02%, 81.93%, and 76.92% for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 78.02% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 83.60% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 72.04% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 79.76% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 72.78% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 73.05% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 80.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.02% |
| Jun 30, 2025 | 81.93% |
| Dec 31, 2024 | 76.92% |
| Jun 30, 2024 | 77.52% |
| Dec 31, 2023 | 74.02% |
| Jun 30, 2023 | 73.47% |
| Mar 31, 2023 | 1,543,209.88% |
| Dec 31, 2022 | 72.27% |
| Sep 30, 2022 | 0.42% |
| Jun 30, 2022 | 73.03% |
| Mar 31, 2022 | 13,229,571.98% |
| Dec 31, 2021 | 0.06% |
| Sep 30, 2021 | -65.63% |
| Jun 30, 2021 | 72.40% |
| Mar 31, 2021 | 4,982,206.41% |
| Dec 31, 2020 | 0.11% |
| Sep 30, 2020 | 7,563,025.21% |
| Jun 30, 2020 | 72.20% |
| Mar 31, 2020 | 74.06% |
| Jun 30, 2019 | 73.26% |